Literature DB >> 27967336

What do we need to make genetic biomarker-guided treatment for renal cell carcinoma a reality?

Meta H Diekstra1, Xiaoyan Liu1, Jesse J Swen1, Henk-Jan Guchelaar1.   

Abstract

Entities:  

Keywords:  SNP; biomarker; pharmacogenetics; renal cell carcinoma; targeted therapy

Mesh：

Substances：

Year:  2016        PMID： 27967336      PMCID： PMC5220441          DOI： 10.2217/pgs-2016-0168

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN： 1462-2416            Impact factor:   2.533


× No keyword cloud information.
  18 in total

Review 1.  Renal cancer.

Authors:  Umberto Capitanio; Francesco Montorsi
Journal:  Lancet       Date:  2015-08-25       Impact factor: 79.321

2.  Hyperbilirubinemia in pazopanib- or sunitinib-treated patients in COMPARZ is associated with UGT1A1 polymorphisms.

Authors:  R J Motzer; T Johnson; T K Choueiri; K C Deen; Z Xue; L N Pandite; C Carpenter; C F Xu
Journal:  Ann Oncol       Date:  2013-10-09       Impact factor: 32.976

3.  CYP3A5 and ABCB1 polymorphisms as predictors for sunitinib outcome in metastatic renal cell carcinoma.

Authors:  Meta H M Diekstra; Jesse J Swen; Epie Boven; Daniel Castellano; Hans Gelderblom; Ron H J Mathijssen; Cristina Rodríguez-Antona; Jesus García-Donas; Brian I Rini; Henk-Jan Guchelaar
Journal:  Eur Urol       Date:  2015-04-27       Impact factor: 20.096

4.  Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study.

Authors:  Jesus Garcia-Donas; Emilio Esteban; Luis Javier Leandro-García; Daniel E Castellano; Aranzazu González del Alba; Miguel Angel Climent; José Angel Arranz; Enrique Gallardo; Javier Puente; Joaquim Bellmunt; Begoña Mellado; Esther Martínez; Fernando Moreno; Albert Font; Mercedes Robledo; Cristina Rodríguez-Antona
Journal:  Lancet Oncol       Date:  2011-10-17       Impact factor: 41.316

5.  Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial.

Authors:  Toni K Choueiri; Bernard Escudier; Thomas Powles; Nizar M Tannir; Paul N Mainwaring; Brian I Rini; Hans J Hammers; Frede Donskov; Bruce J Roth; Katriina Peltola; Jae Lyun Lee; Daniel Y C Heng; Manuela Schmidinger; Neeraj Agarwal; Cora N Sternberg; David F McDermott; Dana T Aftab; Colin Hessel; Christian Scheffold; Gisela Schwab; Thomas E Hutson; Sumanta Pal; Robert J Motzer
Journal:  Lancet Oncol       Date:  2016-06-05       Impact factor: 41.316

Review 6.  Practical guidelines for therapeutic drug monitoring of anticancer tyrosine kinase inhibitors: focus on the pharmacokinetic targets.

Authors:  Huixin Yu; Neeltje Steeghs; Cynthia M Nijenhuis; Jan H M Schellens; Jos H Beijnen; Alwin D R Huitema
Journal:  Clin Pharmacokinet       Date:  2014-04       Impact factor: 6.447

7.  Pharmacogenetics in the cancer clinic: from candidate gene studies to next-generation sequencing.

Authors:  H-J Guchelaar; H Gelderblom; T van der Straaten; J H M Schellens; J J Swen
Journal:  Clin Pharmacol Ther       Date:  2014-01-21       Impact factor: 6.875

8.  Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.

Authors:  Robert J Motzer; Bernard Escudier; David F McDermott; Saby George; Hans J Hammers; Sandhya Srinivas; Scott S Tykodi; Jeffrey A Sosman; Giuseppe Procopio; Elizabeth R Plimack; Daniel Castellano; Toni K Choueiri; Howard Gurney; Frede Donskov; Petri Bono; John Wagstaff; Thomas C Gauler; Takeshi Ueda; Yoshihiko Tomita; Fabio A Schutz; Christian Kollmannsberger; James Larkin; Alain Ravaud; Jason S Simon; Li-An Xu; Ian M Waxman; Padmanee Sharma
Journal:  N Engl J Med       Date:  2015-09-25       Impact factor: 91.245

Review 9.  Lenvatinib therapy for the treatment of patients with advanced renal cell carcinoma.

Authors:  Hilary Glen
Journal:  Future Oncol       Date:  2016-06-24       Impact factor: 3.404

Review 10.  Translating pharmacogenomics: challenges on the road to the clinic.

Authors:  Jesse J Swen; Tom W Huizinga; Hans Gelderblom; Elisabeth G E de Vries; Willem J J Assendelft; Julia Kirchheiner; Henk-Jan Guchelaar
Journal:  PLoS Med       Date:  2007-08       Impact factor: 11.069
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.